Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4276786 | 1.00 | TSHR (0.51) | TSHRKDM4ELMNAMEN1KMT2A | |
| SCHEMBL7379755 | 0.86 | TSHR (0.54) | TSHRKDM4ELMNAMEN1KMT2A | |
| SCHEMBL7379752 | 0.86 | TSHR (0.54) | TSHRKDM4ELMNAMEN1KMT2A | |
| SCHEMBL10955790 | 0.83 | CA12 (0.52) | KDM4ELMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4626240 | 0.82 | TSHR (0.54) | TSHRKDM4ELMNAMEN1KMT2A | |
| SCHEMBL4626235 | 0.82 | TSHR (0.54) | TSHRKDM4ELMNAMEN1KMT2A | |
| SCHEMBL1877841 | 0.79 | TSHR (0.51) | TSHRKDM4ELMNAMEN1KMT2A | |
| SCHEMBL10958781 | 0.79 | SMN1; SMN2 (0.45) | TSHRLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30713077 | 0.77 | AURKA (0.48) | LMNAMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL28511516 | 0.77 | AURKA (0.48) | LMNAMEN1KMT2ASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608739-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080234281-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-25 | — | — | US | disclosed |
| EP-1730099-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1730099-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092011-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234281-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | TSHR 4737/4885KDM4E 525/4885LMNA 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.